Alzheimers

Identifying new drug targets is critical because many of the Alzheimer’s drugs that have been developed to this point haven’t…

GlobalData’s latest report showcases an analysis of the GLP-1R agonists pipeline in multiple indications, highlighting the areas…

Roche’s trontinemab shows strong early promise in Alzheimer’s, with improved brain delivery, biomarker response, and safety…

While prasinezumab missed its primary endpoint, time-to-event analyses suggest potential in delaying early Parkinson’s disease…

The revival of CNS drug development is being fueled by advancements in neuroimmunology and neurodegeneration, moving beyond…

NICE's rejection of Kisunla raises cost-effectiveness concerns but future approval remains possible pending further evidence

EU regulator cites brain swelling risks, impacting Eisai and Biogen, and sparking concerns over global sales and market perception…

Study confirms ALZmetrix whole blood test can detect people at high risk of developing full Alzheimer’s Disease

The unit will provide support to individuals with neurological conditions such as Alzheimer's, Dementia, and Parkinson's, through…

Brexpiprazole was previously approved in the US to treat adults with major depressive disorder and schizophrenia